文献速递鼻科

遗传性出血性毛细血管扩张症鼻出血药物治疗的疗效与安全性

Efficacy and Safety of Various Medications in the Treatment of Hereditary Hemorrhagic Telangiectasia Epistaxis.
PubMed 文献 · Otolaryngol Head Neck Surg · 2026-09-11

该系统综述纳入评估贝伐珠单抗、多西环素、氨甲环酸或β受体阻滞剂治疗遗传性出血性毛细血管扩张症自发性鼻出血的随机对照试验,发现无药物在主要终点上显示一致且临床稳健的优效性;贝伐珠单抗可能适度减少出血频率,氨甲环酸增加腹泻风险而无明确疗效。

要点

  • 氨甲环酸未显著改善鼻出血持续时间、频率或血红蛋白,且增加腹泻风险(OR 3.8,95%CI 1.7-8.5)。
  • 贝伐珠单抗适度减少鼻出血频率(SMD -0.25,95%CI -0.47至-0.02),对其他终点无显著影响。
  • 多西环素及β受体阻滞剂未显示显著获益,药物治疗HHT鼻出血仍不理想。

核心结论

  • 无药物在主要终点上显示一致且临床稳健的优效性。
  • 贝伐珠单抗可能适度减少出血负担,氨甲环酸增加胃肠道毒性而无明确疗效。
  • HHT相关鼻出血的药物控制仍不理想,需要足够把握度的试验与标准化结局指标。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Scopus、Embase、Web of Science和Cochrane Library截至2025年8月。
  • 纳入评估贝伐珠单抗、多西环素、氨甲环酸或β受体阻滞剂对比安慰剂或标准治疗的随机对照试验。

主要发现

  • 氨甲环酸未显著减少鼻出血持续时间或频率,未改善血红蛋白,未改变输血或急诊需求,但增加腹泻(OR 3.8,95%CI 1.7-8.5)。
  • 贝伐珠单抗适度减少鼻出血频率(SMD -0.25,95%CI -0.47至-0.02),对持续时间、ESS、血红蛋白或生活质量无显著影响。
  • 多西环素对持续时间或频率无显著获益。
  • 局部或全身β受体阻滞剂对ESS、生活质量、血红蛋白或总体不良事件无显著影响。
  • 研究间异质性一般低至中等,置信区间较宽,反映样本量有限。

关键数值与推荐

  • 氨甲环酸增加腹泻的OR为3.8(95%CI 1.7-8.5)。
  • 贝伐珠单抗减少鼻出血频率的SMD为-0.25(95%CI -0.47至-0.02)。

临床怎么用

  • 贝伐珠单抗可考虑用于适度减少HHT鼻出血频率,但需权衡有限疗效。
  • 氨甲环酸应慎用,因增加腹泻风险且无明确疗效。
  • 多西环素和β受体阻滞剂缺乏显著获益证据,不推荐常规用于HHT鼻出血。

局限性

  • 纳入研究样本量有限,置信区间较宽。
  • 研究间异质性一般低至中等。
  • 需要足够把握度的试验与标准化结局指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the efficacy and safety of pharmacologic therapies for spontaneous epistaxis in hereditary hemorrhagic telangiectasia (HHT). DATA SOURCES: PubMed, Scopus, Embase, Web of Science, and the Cochrane Library were systematically searched up to August 2025. REVIEW METHODS: Eligible randomized controlled trials evaluating bevacizumab, doxycycline, tranexamic acid, or β-blockers versus placebo or standard care were included. Outcomes included epistaxis frequency and duration, hemoglobin (Hb), epistaxis severity score (ESS), transfusion or emergent-care requirements, quality of life (QOL), and adverse events. RESULTS: Tranexamic acid did not significantly reduce epistaxis duration or frequency or improve Hb, and it did not change transfusion or emergent-care needs, but it increased diarrhea (odds ratio 3.8, 95% confidence interval [CI] [1.7; 8.5]). Bevacizumab produced a modest reduction in epistaxis frequency (standardized mean difference -0.25, 95% CI [-0.47; -0.02]), without significant effects on duration, ESS, Hb, or QOL. Doxycycline showed no significant benefit for duration or frequency. Topical or systemic β-blockers did not significantly affect ESS, QOL, Hb, or overall adverse events. Across agents, between-study heterogeneity was generally low to moderate and CIs were wide, reflecting limited sample sizes. CONCLUSION: No pharmacologic agent demonstrated consistent, clinically robust superiority over placebo across primary endpoints. Bevacizumab may modestly reduce bleeding burden, whereas tranexamic acid increases gastrointestinal toxicity without clear efficacy. Pharmacologic control of HHT-related epistaxis remains suboptimal, underscoring the need for adequately powered trials with standardized outcome measures and optimized dosing and delivery strategies.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Kang YJ, Kim MS, Stybayeva G, et al. Efficacy and Safety of Various Medications in the Treatment of Hereditary Hemorrhagic Telangiectasia Epistaxis. Otolaryngol Head Neck Surg. 2026. PMID: 42726924. doi:10.1002/ohn.70428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。